Loading…
← CockpitCompetitor Analysis › 002390.SZ Guizhou Xinbang Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Guizhou Xinbang Pharmaceutical Co., Ltd. Class A002390.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 85
Mkt cap
$771M
US dollars, full cap
Free float
54%
of shares outstanding
$/day
$11.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.9 pp
WACC 7.4%
Hurdle
-3 pp
Req g minus delivered
Next earnings
153 days
20 Apr 2027
Close · CNYCN¥2.92
1D-1.0%
1W-2.7%
1M+2.5%
3M-6.7%
6M-7.3%
YTD-9.3%
1Y-24.6%
ATR %2.5%
52w lowhigh29.6% off high

What Guizhou Xinbang Pharmaceutical does

Employees: 4,702

Guizhou Xinbang Pharmaceutical at a glance

Size Guizhou Xinbang Pharmaceutical (002390.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $771M, the 2667th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.92 on 18 Nov 2026.

Performance Over six months the shares fell 7.3%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 19 in its peer set.

Growth Revenue fell 12.5% over the last twelve months (peer median +7.3%); the operating margin is 4.5% (peer median 10.4%).

Valuation It trades at 0.9× enterprise value to sales against a peer median of 2.6× (2nd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -3 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 2.9 points below its cost of capital (7.4% WACC).

Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 97002390.SZ 93
Six months, rebased to 100: Guizhou Xinbang Pharmaceutical against the median of its 20 peers (local-currency closes).

Guizhou Xinbang Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥5.02BCN¥5.61BCN¥6.02BCN¥6.45BCN¥6.33B
Revenue growth—-7%-7%+2%—
Gross profitCN¥956MCN¥878MCN¥915MCN¥1.11BCN¥1.08B
EBITDAn/aCN¥449MCN¥498MCN¥654MCN¥580M
Net incomeCN¥138MCN¥120MCN¥101MCN¥287MCN¥224M
Free cash flowCN¥899MCN¥667MCN¥514MCN¥666MCN¥466M
Capital expenditureCN¥45.0MCN¥85.4MCN¥125MCN¥136MCN¥159M
Total debtCN¥541MCN¥681MCN¥1.06BCN¥1.08BCN¥1.66B

Quarterly statements and history in the cockpit →

Guizhou Xinbang Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-50%-25%0%+25%LXRX3001BLISSGVS000411ARDX0023490024240029072171IRWDGUDORIC600479SANOFIRIGL688073COLL002390.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Guizhou Xinbang Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×250×500×750×LXRX3001BLISSGVS000411ARDX0024242171GUDSUVEN002390.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Guizhou Xinbang Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%3001BLISSGVS002349002424002907GUD600479SANOFIRIGL688073COLL002390.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Guizhou Xinbang Pharmaceutical is the large dot.

Guizhou Xinbang Pharmaceutical competitors and peer comparison

How Guizhou Xinbang Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Guizhou Xinbang Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002390.SZPeer medianRank in peer set
1-month return+2.5%-3.8%7th highest of 19
6-month return-7.3%-4.7%9th lowest of 19
Distance from 52-week high-29.6%-33.9%6th highest of 19
Revenue growth (TTM)-12.5%+7.3%3rd lowest of 19
Operating margin4.5%10.4%7th lowest of 19
EV / Sales0.9×2.6×2nd cheapest of 18
Growth the price implies (Req g, 7 yrs)-3.8%6.6%least demanding of 12
Growth delivered (Del g)-0.8%+2.6%3rd lowest of 12
Hurdle (Req g minus delivered)-3.1 pp-2.0 pp6th least demanding of 12
ROIC minus cost of capital-2.9 pp+1.2 pp4th lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Guizhou Xinbang Pharmaceutical 002390.SZChina$771M-7%-13%4%0.9×-3.8%-0.8%
Lexicon Pharmaceuticals LXRXUnited States$766M-22%-46%-147%16.7×n/an/a
Katakura Industries 3001.TJapan$765M+40%-2%15%2.4×0.3%+0.5%
Bliss GVS Pharma BLISSGVS.NSIndia$777M+141%+25%18%6.7×33.9%+10.1%
Sichuan Neautus Traditional Chinese 2206.HKHong Kong$779Mn/a+7%8%n/an/an/a
Zhejiang Int'l 000411.SZChina$783M-21%+3%3%0.3×n/an/a
Ardelyx ARDXUnited States$784M-50%+18%-8%1.6×n/an/a
Jinghua Pharmaceutical 002349.SZChina$785M-8%+2%20%3.1×-2.5%+2.6%
Guizhou Bailing Group Pharmaceutical 002424.SZChina$755M-20%-25%2%2.5×13.5%-0.2%
Chongqing Pharscin Pharmaceutical 002907.SZChina$752M-7%+8%10%5.3×9.4%-1.4%
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
CARsgen Therapeutics 2171.HKHong Kong$751M-45%+68%-170%28.6×n/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Zhuzhou Qianjin Pharmaceutical 600479.SSChina$746M-3%+4%11%1.4×-2.1%0.0%
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%

Questions

Which companies are Guizhou Xinbang Pharmaceutical's closest peers?
The cockpit's peer set: Lexicon Pharmaceuticals (LXRX), Katakura Industries (3001.T), Bliss GVS Pharma (BLISSGVS.NS), Sichuan Neautus Traditional Chinese (2206.HK), Zhejiang Int'l (000411.SZ), Ardelyx (ARDX), Jinghua Pharmaceutical (002349.SZ), Guizhou Bailing Group Pharmaceutical (002424.SZ).
Is Guizhou Xinbang Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 0.9× against a peer median of 2.6×, 2nd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -3 pp: the price already allows for a slowdown.
How has Guizhou Xinbang Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -7.3% against -4.7% for the median peer; over one year -24.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.